Volume 22, No 11, Nov 2012
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 22 Issue 11, November 2012: 1521-1523
RESEARCH HIGHLIGHTS
In vivo reprogramming for heart disease
Huansheng Xu1,2, B Alexander Yi1,2 and Kenneth R Chien1,2
1Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA;
2Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
Correspondence: Kenneth R Chien,(kchien@harvard.edu)
The term “lineage reprogramming” is typically used to describe the conversion of one differentiated somatic cell type into another without transit through a pluripotent intermediate. Two recent reports in Nature demonstrate that such a conversion can be achieved in the heart in situ, and suggest a novel, regenerative approach for the development of cardiac therapeutics.
Cell Research (2012) 22:1521-1523. doi:10.1038/cr.2012.101; published online 3 July 2012
FULL TEXT | PDF
Browse 2258
